Should You Buy NeoGenomics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, NeoGenomics, Inc. (NEO) occupies a solid middle-ground position with a Quality of Company score of 6.9/10. At the current market price of $14.24, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 1 of 12 CirclFi valuation models project upside for NeoGenomics, Inc. (NEO) at $14.24 — the model consensus leans bearish, with a Quality Score of 6.9/10 and Value-Trap risk of 25/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $15.21 (+6.8% upside)
The Bear Case
Target: $0.18 (-98.8%)
- According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $0.18 (-98.8%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +105.6% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
The Bottom Line
Our valuation engine sends a clear cautionary signal on NeoGenomics, Inc. at $14.24. 11/12 models flag overvaluation, composite fair value sits at $4.94 (-65.3%), and the risk-reward profile appears unfavorable. Quality at 6.9/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. NeoGenomics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy NEO stock right now?
Based on CirclFi's multi-model analysis, 1 of 12 models see upside for NEO at $14.24. The models are divided, which means the investment case depends heavily on your assumptions about NeoGenomics, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in NeoGenomics, Inc.?
Key risks include: wide model disagreement (8530% spread), signaling high uncertainty; general market and sector-specific risks affecting Services-Testing Laboratories companies. Always diversify and consult a financial advisor.
How does NEO compare to its competitors?
Among Services-Testing Laboratories peers, NEO holds a Quality Score of 6.9/10. Comparable companies include ULS (QOC 9.7), BNBX (QOC 5.4). The relative ranking helps investors identify whether NEO offers better fundamental quality than alternatives in the same sector.
Is NEO a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NEO's Quality Score of 6.9/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy NEO at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $0.18 to $15.21. At $14.24, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for NEO.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad